Department of Oral and Maxillofacial Surgery, The Affiliated Stomatological Hospital of Nanjing Medical University, Jiangsu, 210029, China.
Jiangsu Key Laboratory of Oral Disease, Nanjing Medical University, Jiangsu, 210029, China.
Adv Sci (Weinh). 2024 Oct;11(40):e2404476. doi: 10.1002/advs.202404476. Epub 2024 Aug 29.
Super-enhancers (SEs) have been recognized as key epigenetic regulators underlying cancer stemness and malignant traits by aberrant transcriptional control and promising therapeutic targets against human cancers. However, the SE landscape and their roles during head and neck squamous cell carcinoma (HNSCC) development especially in cancer stem cells (CSCs) maintenance remain underexplored yet. Here, we identify leukemia inhibitory factor (LIF)-SE as a representative oncogenic SE to activate LIF transcription in HNSCC. LIF secreted from cancer cells and cancer-associated fibroblasts promotes cancer stemness by driving SOX2 transcription in an autocrine/paracrine manner, respectively. Mechanistically, enhancer elements E1, 2, 4 within LIF-SE recruit SOX2/SMAD3/BRD4/EP300 to facilitate LIF transcription; LIF activates downstream LIFR-STAT3 signaling to drive SOX2 transcription, thus forming a previously unknown regulatory feedback loop (LIF-SE-LIF/LIFR-STAT3-SOX2) to maintain LIF overexpression and CSCs stemness. Clinically, increased LIF abundance in clinical samples correlate with malignant clinicopathological features and patient prognosis; higher LIF concentrations in presurgical plasma dramatically diminish following cancer eradication. Therapeutically, pharmacological targeting LIF-SE-LIF/LIFR-STAT3 significantly impairs tumor growth and reduces CSC subpopulations in xenograft and PDX models. Our findings reveal a hitherto uncharacterized LIF-SE-mediated auto-regulatory loop in regulating HNSCC stemness and highlight LIF as a novel noninvasive biomarker and potential therapeutic target for HNSCC.
超级增强子(SEs)已被认为是通过异常转录控制和有前途的人类癌症治疗靶点来支持癌症干性和恶性特征的关键表观遗传调节剂。然而,SE 景观及其在头颈部鳞状细胞癌(HNSCC)发展中的作用,尤其是在癌症干细胞(CSCs)维持方面,仍未得到充分探索。在这里,我们确定白血病抑制因子(LIF)-SE 作为一种代表性的致癌 SE,可激活 HNSCC 中的 LIF 转录。癌细胞和癌症相关成纤维细胞分泌的 LIF 通过自分泌/旁分泌方式分别驱动 SOX2 转录,从而促进癌症干性。在机制上,LIF-SE 内的增强子元件 E1、2、4 招募 SOX2/SMAD3/BRD4/EP300 以促进 LIF 转录;LIF 激活下游的 LIFR-STAT3 信号通路,驱动 SOX2 转录,从而形成一个以前未知的调节反馈环(LIF-SE-LIF/LIFR-STAT3-SOX2),以维持 LIF 的过表达和 CSCs 的干性。临床上,临床样本中 LIF 的丰度增加与恶性临床病理特征和患者预后相关;癌症消除后,术前血浆中的 LIF 浓度显著降低。在治疗上,药物靶向 LIF-SE-LIF/LIFR-STAT3 可显著抑制肿瘤生长,并减少异种移植和 PDX 模型中的 CSC 亚群。我们的研究结果揭示了一个以前未被描述的 LIF-SE 介导的自我调节环,用于调节 HNSCC 干性,并强调 LIF 作为一种新的非侵入性生物标志物和潜在的 HNSCC 治疗靶点。